Our Technology

At OnCuRNA, our novel nanohydrogel system (SANGs) enhances the delivery of therapeutic payloads to solid tumors, offering unprecedented control over drug release, targeting, and efficacy. Our SANGs platform is agnostic to the solid tumor type and to drug payload, making it well suited across multiple oncological indications. Currently, our technology has demonstrated success in four solid tumor models and advanced stage metastasis models, offering hope for more effective cancer treatment solutions.